Hence, we focused our efforts on the development of Tregs against GAD65, which exhibits a high autoantigen density in T1D (45) and is the target of persistent autoimmunity, as evidenced by maintenance of autoantibodies (46). This evidence concerns the gene GAD2 and type 1 diabetes mellitus.